{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:20:09Z","timestamp":1770535209659,"version":"3.49.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/13543784.2021.1948999","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T23:16:59Z","timestamp":1624663019000},"page":"837-855","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Bladder cancer: shedding light on the most promising investigational drugs in clinical trials"],"prefix":"10.1080","volume":"30","author":[{"given":"Irbaz","family":"Bin Riaz","sequence":"first","affiliation":[{"name":"Divison of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6982-8418","authenticated-orcid":false,"given":"Ahsan Masood","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Louisville, Louisville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James WF","family":"Catto","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, University of Sheffield Medical School, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, Academic Unit of Oncology, University of Sheffield Medical School, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.024"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.084"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01665"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010131"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160053"},{"key":"e_1_3_4_14_1","article-title":"Pembrolizumab for Non\u2013muscle-invasive bladder cancer\u2014a costly therapy in search of evidence","author":"Gill J","year":"2020","unstructured":"Gill J, Prasad V. Pembrolizumab for Non\u2013muscle-invasive bladder cancer\u2014a costly therapy in search of evidence. JAMA Oncol. 2020;7:501.","journal-title":"JAMA Oncol"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165840"},{"issue":"4","key":"e_1_3_4_16_1","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of bacillus Calmette-Guerin shortage","volume":"21","author":"Golla V","year":"2019","unstructured":"Golla V, Lenis AT, Faiena I, et al. Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of bacillus Calmette-Guerin shortage. Rev Urol. 2019;21(4):145\u2013153.","journal-title":"Rev Urol"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30586-6"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"e_1_3_4_20_1","unstructured":"Riaz IB. Antibody-drug conjugates for treatment of urothelial carcinoma ASCO daily news2020; [cited 2020 Mar 12]. Available from: https:\/\/dailynews.ascopubs.org\/do\/10.1200\/ADN.20.200381\/full"},{"issue":"4","key":"e_1_3_4_21_1","first-page":"313","article-title":"A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients","volume":"15","author":"Kowalski M","year":"2010","unstructured":"Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010 Nov;15(4):313\u2013320.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_4_22_1","first-page":"2018","article-title":"vista, phase 3 trial of vicinium, an epcam targeted pseudomonas exotoxin, in bcg unresponsive non muscle invasive bladder cancer","author":"Dickstein R","year":"2018","unstructured":"Dickstein R, editor. vista, phase 3 trial of vicinium, an epcam targeted pseudomonas exotoxin, in bcg unresponsive non muscle invasive bladder cancer. Bladder Congr. 2018:2018.","journal-title":"Bladder Congr"},{"issue":"2","key":"e_1_3_4_23_1","first-page":"1","article-title":"33rd annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2018): late-Breaking Abstracts: washington, D.C., USA. 7-11 November 2018","volume":"6","year":"2018","unstructured":"David Fabrizio, PhD1, Shu-Jen Chen, et al.33rd annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2018): late-Breaking Abstracts: washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018;6(Suppl2):1\u201313.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_24_1","unstructured":"QUILT-3.032. A multicenter clinical trial of intravesical Bacillus Calmette-Guerin (BCG) in combination with ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer [Internet]; ClinicalTrials.gov; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03022825?term=ALT-803."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.05.011"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000585"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2409"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.438"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.03.001"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.026"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0623"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3342"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1210"},{"key":"e_1_3_4_45_1","unstructured":"Opdivo Significantly Improves Disease Free-Survival vs. Placebo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma in phase 3 CheckMate \u2212274 trial [Internet]; 2020 [cited 2020 Sep 24]. Available from: https:\/\/www.urotoday.com\/recent-abstracts\/urologic-oncology\/bladder-cancer\/124764-opdivo-nivolumab-significantly-improves-disease-free-survival-vs-placebo-as-adjuvant-therapy-for-patients-with-high-risk-muscle-invasive-urothelial-carcinoma-in-phase-3-checkmate-274-trial.html"},{"key":"e_1_3_4_46_1","unstructured":"Testing MK-3475 (Pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR); 2021 [cited 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244384"},{"issue":"15","key":"e_1_3_4_47_1","article-title":"A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA)","volume":"37","author":"Powles T","year":"2019","unstructured":"Powles T, Meeks JJ, Galsky MD, et al. A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). J clin oncol. 2019;37(15_suppl):TPS4592\u2013TPS4592.","journal-title":"J clin oncol"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13900"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.020"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2015.02.002"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.09.006"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00185"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70162-1"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6699"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01213"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_4_59_1","unstructured":"ESMO Virtual Congress. Pembrolizumab combined with chemotherapy vs chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361 [Internet]. ESMO virtual congress 2020; 2020; [cited 2020 Sep 21]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2020\/bladder-cancer\/124537-esmo-virtual-congress-2020-pembrolizumab-combined-with-chemotherapy-vs-chemotherapy-alone-as-first-line-therapy-for-advanced-urothelial-carcinoma-keynote-361.html"},{"key":"e_1_3_4_60_1","unstructured":"Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable Stage IV bladder cancer [Internet]. 2020; [2020 Mar 06]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03091"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_4_64_1","unstructured":"Phase 3 EV-301 trial of enfortumab vedotin-ejfv meets primary end point for urothelial cancer [Internet]; Cancer Network; 2020. EV\u2013301; [2020 Sept 18]. Available from: https:\/\/www.cancernetwork.com\/view\/phase-3-ev-301-trial-of-enfortumab-vedotin-ejfv-meets-primary-end-point-for-urothelial-cancer"},{"key":"e_1_3_4_65_1","unstructured":"ASCO GU 2020: study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma; ASCO GU 2020; 2020. urotoday.com."},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.6_suppl.384"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0229"},{"key":"e_1_3_4_70_1","first-page":"2020","article-title":"TROPHY-U-01 Cohort 1 final results: a phase 2 study of Sacituzumab Govitecan (SG) in metastatic urothelial cancer that has progressed after platinum and checkpoint inhibitors","volume":"2020","author":"ESMO Virtual Congress","year":"2020","unstructured":"ESMO Virtual Congress. TROPHY-U-01 Cohort 1 final results: a phase 2 study of Sacituzumab Govitecan (SG) in metastatic urothelial cancer that has progressed after platinum and checkpoint inhibitors. ESMO Virtual Cong. 2020;2020:2020.","journal-title":"ESMO Virtual Cong"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5027"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1948999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:46:43Z","timestamp":1732610803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1948999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/13543784.2021.1948999"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1948999","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}